September 6, 2006 – EpiCept lost almost one-third of its value after reporting that LidoPAIN, a sterile analgesic patch, did not diminish pain in a Phase III trial; the FDA advisory committee refused to recommend the cancer drug Genasense from Genta; Genzyme treated the first leukemia adult patient in a Phase III trial of Clolar; XOMA received orphan drug designation in Europe for Neuprex; SkyePharma out-licensed European rights for Flutiform, a therapy for asthma and COPD; Lexicon Genetics began a Phase I trial of a compound for cognitive disorders; ZymoGenetics reported positive data from a Phase III trial of its recombinant human thrombin product, and Medarex began a Phase II trial of two drugs for C. difficile associated diarrhea. The Centient Biotech 200™ dropped 66 points to close at 3716.6, a loss of 1.75%. More details...
